Changeflow GovPing Healthcare & Life Sciences Surrozen Operating Inc. Secures Anti-Frizzled A...
Routine Notice Added Final

Surrozen Operating Inc. Secures Anti-Frizzled Antibody Patent

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO granted Patent US12606629B2 to Surrozen Operating, Inc. on April 21, 2026. The patent covers monospecific anti-Frizzled monoclonal antibodies and related compositions for therapeutic applications. The application, filed July 2, 2020, received 10 claims under CPC classifications including C07K 16/2863.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO granted Surrozen Operating, Inc. a patent for monospecific anti-Frizzled monoclonal antibodies and their use in therapeutic methods for disease treatment. The patent covers the antibodies themselves and methods of treatment using them.

For competitors in the Wnt/Frizzled signaling pathway space, this grant establishes IP protection around a specific antibody class. While the patent does not impose compliance obligations on third parties, firms developing similar anti-Fzd therapeutics should review this IP landscape to assess freedom-to-operate considerations.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Monospecific anti-frizzled antibodies and methods of use

Grant US12606629B2 Kind: B2 Apr 21, 2026

Assignee

Surrozen Operating, Inc.

Inventors

Yang Li, Thomas Steven Lopez, I-Chieh Wang, Parthasarathy Sampathkumar

Abstract

The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

CPC Classifications

C07K 16/2863 C07K 16/28 C07K 2317/31 C07K 2317/33 C07K 2317/52 C07K 2317/55 C07K 2317/569 C07K 2317/64 C07K 2317/71 C07K 2317/75 C07K 2299/00 C07K 2317/92 C07K 2319/00 A61K 38/00

Filing Date

2020-07-02

Application No.

17623006

Claims

10

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent granting Biotechnology R&D Antibody therapeutics
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!